Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory Therapeutics

Journal of Medicinal Chemistry

Volumn 58, Issue 11, 2015, Pages 4727-4737

  Luz, John Gately ^a   Antonysamy, Stephen ^a   Kuklish, Steven L ^a   Condon, Bradley ^a   Lee, Matthew R ^a   Allison, Dagart ^a   Yu, Xiao Peng ^a   Chandrasekhar, Srinivasan ^a   Backer, Ryan ^a   Zhang, Aiping ^a   Russell, Marijane ^a   Chang, Shawn S ^a   Harvey, Anita ^a   Sloan, Ashley V ^a   Fisher, Matthew J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ISOMERASE INHIBITOR; MICROSOMAL PROSTAGLANDIN E SYNTHASE 1 INHIBITOR; PROSTAGLANDIN E SYNTHASE 1; UNCLASSIFIED DRUG; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; ISOMERASE; PROSTAGLANDIN E SYNTHASE;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; HUMAN; IC50; LIGHT SCATTERING; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THERMOSTABILITY; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; METABOLISM; MICROSOME; MOLECULAR GENETICS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANALGESICS; ANTI-INFLAMMATORY AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; INTRAMOLECULAR OXIDOREDUCTASES; MICROSOMES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84935919713     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00330     Document Type: Article

References (45)

1. Hinz, B.; Cheremina, O.; Brune, K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man FASEB J. 2008, 22, 383 - 390
2. Loll, P. J.; Picot, D.; Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase Nat. Struct. Biol. 1995, 2, 637 - 643
3. Serhan, C. N.; Maddox, J. F.; Petasis, N. A.; Akritopoulou-Zanze, I.; Papayianni, A.; Brady, H. R.; Colgan, S. P.; Madara, J. L. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils Biochemistry 1995, 34, 14609 - 14615
4. Clish, C. B.; O'Brien, J. A.; Gronert, K.; Stahl, G. L.; Petasis, N. A.; Serhan, C. N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8247 - 8252
5. Xiao, G.; Tsai, A. L.; Palmer, G.; Boyar, W. C.; Marshall, P. J.; Kulmacz, R. J. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2 Biochemistry 1997, 36, 1836 - 1845
6. Hall, S. M.; Plaster, P. A.; Glasgow, J. F.; Hancock, P. Preadmission antipyretics in Reye's syndrome Arch. Dis. Child. 1988, 63, 857 - 866
7. Hennan, J. K.; Huang, J.; Barrett, T. D.; Driscoll, E. M.; Willens, D. E.; Park, A. M.; Crofford, L. J.; Lucchesi, B. R. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries Circulation 2001, 104, 820 - 825
8. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N. Engl. J. Med. 2005, 352, 1092 - 1102
9. Juni, P.; Nartey, L.; Reichenbach, S.; Sterchi, R.; Dieppe, P. A.; Egger, M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 2004, 364, 2021 - 2029
10. Solomon, D. H.; Schneeweiss, S.; Glynn, R. J.; Kiyota, Y.; Levin, R.; Mogun, H.; Avorn, J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 2004, 109, 2068 - 2073
11. Korotkova, M.; Jakobsson, P. J. Characterization of microsomal prostaglandin E synthase 1 inhibitors Basic Clin. Pharmacol. Toxicol. 2014, 114, 64 - 69
12. Howe, L. R.; Subbaramaiah, K.; Kent, C. V.; Zhou, X. K.; Chang, S. H.; Hla, T.; Jakobsson, P. J.; Hudis, C. A.; Dannenberg, A. J. Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis Prostaglandins Other Lipid Mediators 2013, 106, 99 - 105
13. Finetti, F.; Terzuoli, E.; Bocci, E.; Coletta, I.; Polenzani, L.; Mangano, G.; Alisi, M. A.; Cazzolla, N.; Giachetti, A.; Ziche, M.; Donnini, S. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis PLoS One 2012, 7, e40576
14. Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Iñiguez, M. A.; Hanaka, H.; Fresno, M.; Ràdmark, O.; Ziche, M. EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity Oncogene 2012, 31, 3457 - 3466
15. Sasaki, Y.; Kamei, D.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Murakami, M.; Hara, S. Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis Oncogene 2012, 31, 2943 - 2952
16. Oshima, H.; Oshima, M.; Inaba, K.; Taketo, M. M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice EMBO J. 2004, 23, 1669 - 1678
17. Isono, M.; Suzuki, T.; Hosono, K.; Hayashi, I.; Sakagami, H.; Uematsu, S.; Akira, S.; DeClerck, Y. A.; Okamoto, H.; Majima, M. Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice Life Sci. 2011, 88, 693 - 700
18. Kamei, D.; Murakami, M.; Sasaki, Y.; Nakatani, Y.; Majima, M.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Hara, S.; Kudo, I. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis Biochem. J. 2009, 425, 361 - 371
19. Wilhelms, D. B.; Kirilov, M.; Mirrasekhian, E.; Eskilsson, A.; Kugelberg, U.Ö.; Klar, C.; Ridder, D. A.; Herschman, H. R.; Schwaninger, M.; Blomqvist, A.; Engblom, D. Deletion of prostaglandin E2 synthesizing enzymes in brain endothelial cells attenuates inflammatory fever J. Neurosci. 2014, 34, 11684 - 11690
20. Saha, S.; Engström, L.; Mackerlova, L.; Jakobsson, P. J.; Blomqvist, A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1 Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2002, 288, R1100 - R1107
21. Engblom, D.; Saha, S.; Engström, L.; Westman, M.; Audoly, L. P.; Jakobsson, P. J.; Blomqvist, A. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis Nat. Neurosci. 2003, 6, 1137 - 1138
22. Mabuchi, T.; Kojima, H.; Abe, T.; Takagi, K.; Sakurai, M.; Ohmiya, Y.; Uematsu, S.; Akira, S.; Watanabe, K.; Ito, S. Membrane-associated prostaglandin E synthase-1 is required for neuropathic pain NeuroReport 2004, 15, 1395 - 1398
23. Trebino, C. E.; Stock, J. L.; Gibbons, C. P.; Naiman, B. M.; Wachtmann, T. S.; Umland, J. P.; Pandher, K.; Lapointe, J. M.; Saha, S.; Roach, M. L.; Carter, D.; Thomas, N. A.; Durtschi, B. A.; McNeish, J. D.; Hambor, J. E.; Jakobsson, P. J.; Carty, T. J.; Perez, J. R.; Audoly, L. P. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9044 - 9049
24. Arhancet, G. B.; Walker, D. P.; Metz, S.; Fobian, Y. M.; Heasley, S. E.; Carter, J. S.; Springer, J. R.; Jones, D. E.; Hayes, M. J.; Shaffer, A. F.; Jerome, G. M.; Baratta, M. T.; Zweifel, B.; Moore, W. M.; Masferrer, J. L.; Vazquez, M. L. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation Bioorg. Med. Chem. Lett. 2013, 23, 1114 - 1119
25. Cote, B.; Boulet, L.; Brideau, C.; Claveau, D.; Ethier, D.; Frenette, R.; Gagnon, M.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Massé, F.; Méthot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 6816 - 6820
26. Xu, D.; Rowland, S. E.; Clark, P.; Giroux, A.; Cote, B.; Guiral, S.; Salem, M.; Ducharme, Y.; Friesen, R. W.; Méthot, N.; Mancini, J.; Audoly, L.; Riendeau, D. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation J. Pharmacol. Exp. Ther. 2008, 326, 754 - 763
27. Leclerc, P.; Pawelzik, S. C.; Idborg, H.; Spahiu, L.; Larsson, C.; Stenberg, P.; Korotkova, M.; Jakobsson, P. J. Characterization of a new mPGES-1 inhibitor in rat models of inflammation Prostaglandins Other Lipid Mediators 2013, 102-103, 1 - 12
28. Ferguson, A. D.; McKeever, B. M.; Xu, S.; Wisniewski, D.; Miller, D. K.; Yamin, T. T.; Spencer, R. H.; Chu, L.; Ujjainwalla, F.; Cunningham, B. R.; Evans, J. F.; Becker, J. W. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein Science 2007, 317, 510 - 512
29. Ago, H.; Kanaoka, Y.; Irikura, D.; Lam, B. K.; Shimamura, T.; Austen, K. F.; Miyano, M. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis Nature 2007, 448, 609 - 612
30. Sjögren, T.; Nord, J.; Ek, M.; Johansson, P.; Liu, G.; Geschwindner, S. Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the MAPEG superfamily Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3806 - 3811
31. Li, D.; Howe, N.; Dukkipati, A.; Shah, S. T.; Bax, B. D.; Edge, C.; Bridges, A.; Hardwicke, P.; Singh, O. M.; Giblin, G.; Pautsch, A.; Pfau, R.; Schnapp, G.; Wang, M.; Olieric, V.; Caffrey, M. Crystallizing membrane proteins in the lipidic mesophase. Experience with human prostaglandin E2 synthase 1 and an evolving strategy Cryst. Growth Des. 2014, 14, 2034 - 2047
32. Holm, P. J.; Bhakat, P.; Jegerschöld, C.; Gyobu, N.; Mitsuoka, K.; Fujiyoshi, Y.; Morgenstern, R.; Hebert, H. Structural basis for detoxification and oxidative stress protection in membranes J. Mol. Biol. 2006, 360, 934 - 945
33. Schmidt-Krey, I.; Mitsuoka, K.; Hirai, T.; Murata, K.; Cheng, Y.; Fujiyoshi, Y.; Morgenstern, R.; Hebert, H. The three-dimensional map of microsomal glutathione transferase 1 at 6 Å resolution EMBO J. 2000, 19, 6311 - 6316
34. Wu, T. Y.; Juteau, H.; Ducharme, Y.; Friesen, R. W.; Guiral, S.; Dufresne, L.; Poirier, H.; Salem, M.; Riendeau, D.; Mancini, J.; Brideau, C. Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1 Bioorg. Med. Chem. Lett. 2010, 20, 6978 - 6982
35. Riendeau, D.; Aspiotis, R.; Ethier, D.; Gareau, Y.; Grimm, E. L.; Guay, J.; Guiral, S.; Juteau, H.; Mancini, J. A.; Méthot, N.; Rubin, J.; Friesen, R. W. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886 Bioorg. Med. Chem. Lett. 2005, 15, 3352 - 3355
36. Olofsson, K.; Suna, E.; Pelcman, B.; Ozola, V.; Katkevics, M.; Kalvins, I. International Patent Publication WO 2005/123673 A1, 2005.
37. Senisterra, G. A.; Ghanei, H.; Khutoreskaya, G.; Dobrovetsky, E.; Edwards, A. M.; Privé, G. G.; Vedadi, M. Assessing the stability of membrane proteins to detect ligand binding using differential static light scattering J. Biomol. Screening 2010, 15, 314 - 320
38. Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 J. Comput. Chem. 1996, 17, 490 - 519
39. Giroux, A.; Boulet, L.; Brideau, C.; Chau, A.; Claveau, D.; Côté, B.; Ethier, D.; Frenette, R.; Gagnon, M.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Massé, F.; Méthot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5837 - 5841
40. Ouellet, M.; Falgueyret, J.-P.; Ear, P. H.; Pen, A.; Mancini, J. A.; Riendeau, D.; Percival, M. D. Purification and characterization of recombinant microsomal prostaglandin E synthase-1 Protein Expression Purif. 2002, 26, 489 - 495
41. Thorén, S.; Weinander, R.; Saha, S.; Jegerschöld, C.; Pettersson, P. L.; Samuelsson, B.; Hebert, H.; Hamberg, M.; Morgenstern, R.; Jakobsson, P. J. Human microsomal prostaglandin E synthase-1: Purification, functional characterization, and projection structure determination J. Biol. Chem. 2003, 287, 22199 - 22209
42. Sheldrick, G. M. A short history of SHELX Acta Crystallogr., Sect. A 2008, 64, 112 - 122
43. Langer, G.; Cohen, S. X.; Lamzin, V. S.; Perrakis, A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 Nat. Protoc. 2008, 3, 1171 - 1179
44. Murshudov, G. N.; Skubak, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr., Sect. D 2011, 67, 355 - 367
45. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of coot Acta Crystallogr., Sect. D 2010, 66, 486 - 501